DK0808325T3 - Androstan- og pregnanserier til allosterisk modulering af GABA-receptor - Google Patents

Androstan- og pregnanserier til allosterisk modulering af GABA-receptor

Info

Publication number
DK0808325T3
DK0808325T3 DK95942879T DK95942879T DK0808325T3 DK 0808325 T3 DK0808325 T3 DK 0808325T3 DK 95942879 T DK95942879 T DK 95942879T DK 95942879 T DK95942879 T DK 95942879T DK 0808325 T3 DK0808325 T3 DK 0808325T3
Authority
DK
Denmark
Prior art keywords
androstan
pregnancies
gaba receptor
allosteric modulation
allosteric
Prior art date
Application number
DK95942879T
Other languages
English (en)
Inventor
Michael B Bolger
Hasan Tahir
Nancy C Lan
Kelvin W Gee
Robert Purdy
Ravindra B Upasani
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Application granted granted Critical
Publication of DK0808325T3 publication Critical patent/DK0808325T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95942879T 1994-11-23 1995-11-22 Androstan- og pregnanserier til allosterisk modulering af GABA-receptor DK0808325T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34692694A 1994-11-23 1994-11-23
PCT/US1995/015210 WO1996016076A1 (en) 1994-11-23 1995-11-22 Androstane and pregnane series for allosteric modulation of gaba receptor

Publications (1)

Publication Number Publication Date
DK0808325T3 true DK0808325T3 (da) 2001-01-29

Family

ID=23361616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95942879T DK0808325T3 (da) 1994-11-23 1995-11-22 Androstan- og pregnanserier til allosterisk modulering af GABA-receptor

Country Status (27)

Country Link
EP (1) EP0808325B1 (da)
JP (1) JPH10509458A (da)
KR (1) KR100394548B1 (da)
CN (1) CN1171114A (da)
AP (1) AP653A (da)
AT (1) ATE198753T1 (da)
AU (1) AU707486B2 (da)
BR (1) BR9509764A (da)
CA (1) CA2205919A1 (da)
CZ (1) CZ292881B6 (da)
DE (1) DE69519945T2 (da)
DK (1) DK0808325T3 (da)
ES (1) ES2155543T3 (da)
FI (1) FI972202A (da)
GE (1) GEP20002033B (da)
GR (1) GR3035562T3 (da)
HU (1) HUT77087A (da)
IL (1) IL116108A (da)
IS (1) IS4488A (da)
MX (1) MX9703826A (da)
NO (1) NO308950B1 (da)
NZ (1) NZ298567A (da)
PL (1) PL182898B1 (da)
PT (1) PT808325E (da)
RU (1) RU2176248C2 (da)
UA (1) UA48154C2 (da)
WO (1) WO1996016076A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
UA57706C2 (uk) * 1995-06-06 2003-07-15 Косенсіз, Інк Нейроактивні стероїди ряду андростанів та прегнанів, фармацевтична композиція і спосіб лікування (варіанти)
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
DE69927960T2 (de) 1998-03-11 2006-07-20 Torbjörn Backström Epiallopregnanolon zur behandlung von krankheiten des cns
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
MXPA02006079A (es) 1999-12-20 2004-08-23 Nicholas J Kerkhof Proceso para producir particulas de nanometro mediante secado por aspersion de lecho fluido.
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009005335A (es) * 2006-11-21 2009-06-08 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103819525A (zh) * 2008-05-20 2014-05-28 梅克芳股份公司 甾族化合物
CN103880909A (zh) * 2008-05-20 2014-06-25 梅克芳股份公司 甾族化合物
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2524724T3 (es) * 2009-08-13 2014-12-11 Marinus Pharmaceuticals, Inc. Método para preparar 3alfa-hidroxi,3beta-metil-5alfa-pregnán-20-ona (ganaxolona)
JP5687287B2 (ja) 2010-01-14 2015-03-18 ウメクライン ムード エービー 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物
US20130245253A1 (en) * 2010-03-26 2013-09-19 Department Of Veterans Affairs Conjugated Neuroactive Steroid Compositions And Methods Of Use
EP2736919A4 (en) * 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US20150291654A1 (en) * 2011-10-14 2015-10-15 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
CN112472814A (zh) 2012-01-23 2021-03-12 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
PT2887944T (pt) * 2012-08-21 2022-01-10 Sage Therapeutics Inc Alopregnanolona para tratamento do estado de mal epiléptico refratário
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JP6255082B2 (ja) 2013-03-13 2017-12-27 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイドおよびその使用方法
EP3909966A1 (en) 2013-04-17 2021-11-17 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
RS61733B1 (sr) 2013-07-19 2021-05-31 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotrebe
PT3488852T (pt) 2013-08-23 2021-02-03 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016036724A1 (en) 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
NZ731095A (en) 2014-10-16 2023-12-22 Sage Therapeutics Inc Compositions and methods for treating cns disorders
NZ731034A (en) 2014-10-16 2024-02-23 Sage Therapeutics Inc Compositions and methods for treating cns disorders
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
JP6745274B2 (ja) 2015-01-26 2020-08-26 セージ セラピューティクス, インコーポレイテッド Cns障害を処置するための組成物および方法
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20180026742A (ko) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
TWI798173B (zh) 2016-03-08 2023-04-11 美商賽吉醫療公司 神經活性類固醇,其組合物及用途
BR112018070123A2 (pt) 2016-04-01 2019-02-05 Sage Therapeutics Inc oxiesterós e métodos de uso dos mesmos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3481845B1 (en) 2016-07-11 2023-09-13 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
US11542296B2 (en) 2018-04-23 2023-01-03 The Texas A&M University System Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders
CA3115805A1 (en) 2018-10-12 2020-04-16 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
CN113383004A (zh) 2018-12-05 2021-09-10 萨奇治疗股份有限公司 神经活性类固醇及其使用方法
CN111410673A (zh) * 2019-01-08 2020-07-14 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
JOP20210293A1 (ar) 2019-05-31 2023-01-30 Sage Therapeutics Inc ستيرويدات ذات فعالية عصبية وتركيبات منها
US20230257415A1 (en) * 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
TW202143976A (zh) * 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
WO2023023650A1 (en) * 2021-08-20 2023-02-23 University Of Mississippi Allopregnanolone analogues for hiv viremia and neurotoxicity protection
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
US5371077A (en) * 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf

Also Published As

Publication number Publication date
RU2176248C2 (ru) 2001-11-27
CA2205919A1 (en) 1996-05-30
NZ298567A (en) 2000-01-28
CZ292881B6 (cs) 2003-12-17
BR9509764A (pt) 1998-07-07
GR3035562T3 (en) 2001-06-29
ATE198753T1 (de) 2001-02-15
CN1171114A (zh) 1998-01-21
NO972320D0 (no) 1997-05-21
EP0808325A1 (en) 1997-11-26
DE69519945T2 (de) 2001-06-07
FI972202A (fi) 1997-07-17
IL116108A0 (en) 1996-01-31
NO972320L (no) 1997-07-23
IS4488A (is) 1997-05-23
IL116108A (en) 2002-08-14
AP653A (en) 1998-07-21
EP0808325B1 (en) 2001-01-17
MX9703826A (es) 1998-02-28
KR100394548B1 (ko) 2004-02-05
UA48154C2 (uk) 2002-08-15
AU707486B2 (en) 1999-07-08
AU4408596A (en) 1996-06-17
AP9700998A0 (en) 1997-07-31
JPH10509458A (ja) 1998-09-14
ES2155543T3 (es) 2001-05-16
CZ155397A3 (cs) 1998-03-18
PL182898B1 (pl) 2002-03-29
GEP20002033B (en) 2000-04-10
WO1996016076A1 (en) 1996-05-30
PT808325E (pt) 2001-06-29
HUT77087A (hu) 1998-03-02
FI972202A0 (fi) 1997-05-23
PL320416A1 (en) 1997-09-29
DE69519945D1 (de) 2001-02-22
NO308950B1 (no) 2000-11-20
EP0808325A4 (da) 1997-12-17

Similar Documents

Publication Publication Date Title
DK0808325T3 (da) Androstan- og pregnanserier til allosterisk modulering af GABA-receptor
DK1445259T3 (da) Anvendelse af krystalformer for 2-methyl-thieno-benzodiazepin
DE29607627U1 (de) Befestigungs- und Tragevorrichtung für Klingen
DE69616873T2 (de) Überbrückungsvorrichtung für Gelenkprothese
NO954290D0 (no) Festeanordning for protese
DE69625660D1 (de) Spendevorrichtung für chirurgische befestigungsplättchen
DK0781981T3 (da) Fremgangsmåde til tilvejebringelse af en massegennemstrømningsmåleindretning
DE69308433D1 (de) Silikon-Emulsion-Zusammensetzung für Trennbeschichtung
DK0905601T3 (da) System til begrænsning af anvendelsen af et måleapparat
DE69631811D1 (de) Härtbare flüssige Zweikomponenten-Siliconzusammensetzung
DE29503672U1 (de) Verbindungsvorrichtung für Leitungsabschnitte von Installationsregistern
KR970016465U (ko) 부품 조립용 체결장치
DE29508137U1 (de) Befestigungseinrichtung für ein Ausdehnungsgefäß
DK0750635T3 (da) Peptider til inhibering af frigivelsen af pepsin
HUP0003432A3 (en) Device for spanning an expansion joint of a bridge
FR2745922B1 (fr) Dispositif pour rememorer une operation relative a un objet determine et application de ce dispositif
KR960026392U (ko) 이형부품삽입기의 부품고정장치
DK0837874T3 (da) Neuroaktive steroider fra rækken af androstaner og pregnaner
TW379791U (en) Fixing device of pipe
TW492497U (en) Quick fixing device of form
KR970014046U (ko) 배기관의 연결용 고정부재
KR970043220U (ko) 자동변속기의 인히비터 스위치 고정용 클립
KR960006064U (ko) 디지탈 피아노의 소매 스트립(Strip)고정장치
KR970025137U (ko) 손목시계용 달력출력장치
FR2738652B1 (fr) Dispositif de fixation et de tension d'une toile sur un panneau d'affichage et procedes de mise en oeuvre